Affordable Access

Publisher Website

Viral hepatitis and HIV co-infection

Antiviral Research
Publication Date
DOI: 10.1016/j.antiviral.2009.10.021
  • Hepatitis B
  • Hepatitis C
  • Hepatitis Delta
  • Hiv
  • Co-Infection
  • Liver
  • Interferon
  • Ribavirin
  • Entecavir
  • Adefovir
  • Lamivudine
  • Tenofovir
  • Antiviral Drugs
  • Medicine


Abstract Chronic hepatitis B virus (HBV) infection is overall recognised in 10% of HIV+ persons worldwide, with large differences according to geographical region. Chronic hepatitis C virus (HCV) infection affects 25% of HIV+ individuals, with greater rates (∼75%) in intravenous drug users and persons infected through contaminated blood or blood products. HIV-hepatitis co-infected individuals show an accelerated course of liver disease, with faster progression to cirrhosis. The number of anti-HBV drugs has increased in the last few years, and some agents (e.g. lamivudine, emtricitabine, tenofovir) also exert significant activity against HIV. Emergence of drug resistance challenges the long-term benefit of anti-HBV monotherapy, mainly with lamivudine. The results using new more potent anti-HBV drugs (e.g. tenofovir) are very promising, with prospects for stopping or even revert HBV-related liver damage in most cases. With respect to chronic hepatitis C, the combination of pegylated interferon plus ribavirin given for 1 year permits to achieve sustained HCV clearance in no more than 40% of HIV–HCV co-infected patients. Thus, new direct anti-HCV drugs are eagerly awaited for this population. Although being a minority, HIV+ patients with delta hepatitis and those with multiple hepatitis show the worst prognosis. Appropriate diagnosis and monitoring of chronic viral hepatitis, including the use of non-invasive tools for assessing liver fibrosis and measurement of viral load, may allow to confront adequately chronic viral hepatitis in HIV+ patients, preventing the development of end-stage liver disease, for which the only option available is liver transplantation. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

[Co-infection with HIV and viral hepatitis C].

on Médecine et Maladies Infectieu... July 2006

Prevention of viral hepatitis in HIV co-infection

on Journal of Hepatology Jan 01, 2006

Epidemiology of viral hepatitis and HIV co-infecti...

on Journal of Hepatology Jan 01, 2006
More articles like this..